Low pre-infection levels of neutralizing antibody in breakthrough infections after bivalent BA.4–5 vaccine and practical application of dried blood spots

• Published in: Vaccine 2024-09, Vol.42 (22), p.126029, Article 126029
• Main Authors: Kawasuji, Hitoshi, Morinaga, Yoshitomo, Tani, Hideki, Yamada, Hiroshi, Yoshida, Yoshihiro, Ezaki, Masayoshi, Koshiyama, Yuki, Takegoshi, Yusuke, Kaneda, Makito, Murai, Yushi, Kimoto, Kou, Nagaoka, Kentaro, Niimi, Hideki, Yamamoto, Yoshihiro
• Format: Article
• Language: English
• Subjects: Antibodies; BA.5; Bispecific antibodies; Bivalent; Blood; Blood levels; blood serum; Breakthrough infection; COVID-19; COVID-19 infection; COVID-19 vaccines; Dried blood spots; Filter paper; health services; Immune status; Infections; Laboratories; Longitudinal studies; Medical personnel; Medical screening; Neutralizing; Neutralizing antibody; Omicron; risk; Severe acute respiratory syndrome coronavirus 2; temperature; Vaccines; Viruses; XBB.1.5
• ISSN: 0264-410X; 1873-2518; 1873-2518
• DOI: 10.1016/j.vaccine.2024.05.077

The level of neutralizing antibodies required to confer protection against COVID-19 breakthrough infections (BIs) is unclear, and the ability to know the immune status of individuals against the rapidly changing endemic variants is limited. We assessed longitudinal serum anti-RBD antibody levels and neutralizing activities (NTs) against Omicron BA.5 and XBB.1.5 in healthcare workers following the fourth monovalent and fifth bivalent BA.4–5 vaccines. The occurrence of BIs was also followed, and pre-infection antibody levels were compared between patients who developed BI and those who did not. In addition, we collected whole blood samples on the same day as the sera and stored them on filter papers (nos. 545, 590, and 424) for up to two months, then measured their NTs using dried blood spots (DBS) eluates, and compared them with the NTs in paired sera. Pre-infection levels of NTs were lower in patients who developed BI than those who did not, but the anti-RBD antibody levels were not different between them. The NTs below 50 % using 200-fold diluted sera might be one of the indicators of high risk for COVID-19 BI. However, the NTs against XBB.1.5 at 6 months after the fifth dose of bivalent BA.4–5 vaccine were lower than this threshold in almost half of infection-naïve participants. NTs measured using DBS eluates were strongly correlated with those measured using paired sera, but the time and temperature stability varied with the type of filter paper; no. 545 filter paper was found to most suitable for NT evaluation.